Company: KROS
Filing Date: 2025-01-15
Form Type: 8-K
Source: 0001664710-25-000005
Chunk: 0

Company: Keros Therapeutics, Inc.
Filing Date: 2025-01-15
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On January 15, 2025, Keros Therapeutics, Inc. announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension, including the 1.5 mg/kg and placebo treatment arms, based on the ongoing safety review due to new observations of pericardial effusion adverse events. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.